Journey of the ALK-inhibitor CH5424802 to phase II clinical trial
- 23 May 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Archives of Pharmacal Research
- Vol. 36 (9), 1051-1054
- https://doi.org/10.1007/s12272-013-0157-8
Abstract
The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase represents a potential therapeutic target. Specially, a variety of alterations in the ALK gene including mutations, overexpression, amplification, translocations and structural rearrangements, are involved in human cancer tumorigenesis. The second-generation ALK inhibitor CH5424802 (development code: AF802; Chugai Pharmaceutical, a subsidiary of Roche) achieves tumor regression with excellent tolerance and shows promising efficacy in patients with ALK-positive non-small cell lung cancer. CH5424802 shows good kinase selectivity, has a promising pharmacokinetics profile, and has strong antiproliferative activity in several ALK-driven tumor models. CH5424802 has also shown anti-tumor activity in mouse xenograft studies. Here, we summarize recent advances and the evidence that CH5424802 acts as an ALK inhibitor. We also discuss its potential for further development as an anticancer drug in clinical trials.Keywords
This publication has 24 references indexed in Scilit:
- ALK-Mutated Non-Small-Cell Lung Cancer: A New Strategy for Cancer TreatmentLung, 2012
- Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)Bioorganic & Medicinal Chemistry, 2012
- ALK Inhibitors, a Pharmaceutical PerspectiveFrontiers in Oncology, 2012
- Emerging importance of ALK in neuroblastomaSeminars in Cancer Biology, 2011
- 9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase InhibitorsJournal of Medicinal Chemistry, 2011
- Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2011
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic targetNature Medicine, 2005
- Role of the Nucleophosmin (NPM) Portion of the Non-Hodgkin’s Lymphoma-Associated NPM-Anaplastic Lymphoma Kinase Fusion Protein in OncogenesisMolecular and Cellular Biology, 1997
- Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous systemOncogene, 1997